Ascorbic Acid on Restenosis of Dysfunctional Hemodialysis Vascular Access

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the effect of ascorbic acid on angiographic restenosis after percutaneous transluminal angioplasty (PTA) for dysfunctional dialysis vascular access.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Taiwan University Hospital Hsin-Chu Branch
• Treatments: Ascorbic Acid; Vitamins

Criteria

Inclusion Criteria:

• clinical signs, i.e., decreased thrill, development of collateral veins, limb swelling, and prolonged bleeding from puncture sites, suggesting vascular access dysfunction

• reduction of flow rate more than 25% from baseline

• total access blood flow rate less than 500 mL/min by ultrasound dilution method

• increased venous pressure during dialysis, as dynamic venous pressure exceeding threshold levels of 150 mmHg in AVF and 160 mmHg in AVG, respectively, under dialysis blood flow 250 ml/min for three consecutive times

Exclusion Criteria:

• hospitalized for infection, heart failure, or acute coronary syndrome in recent 3 months

• unable to comply with follow-up visits

• already under ascorbic acid or other antioxidant supplements